Primary care clinical management following self-harm during the first wave of COVID-19 in the UK: population-based cohort study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
14 02 2022
Historique:
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 19 2 2022
Statut: epublish

Résumé

A substantial reduction in self-harm recorded in primary care occurred during the first wave of COVID-19 but effects on primary care management of self-harm are unknown. Our objectives were to examine the impact of COVID-19 on clinical management within 3 months of an episode of self-harm. Retrospective cohort study. UK primary care. 4238 patients with an index episode of self-harm recorded in UK primary care during the COVID-19 first-wave period (10 March 2020-10 June 2020) compared with 48 739 patients in a prepandemic comparison period (10 March-10 June, 2010-2019). Using data from the UK Clinical Practice Research Datalink, we compared cohorts of patients with an index self-harm episode recorded during the prepandemic period versus the COVID-19 first-wave period. Patients were followed up for 3 months to capture subsequent general practitioner (GP)/practice nurse consultation, referral to mental health services and psychotropic medication prescribing. We examined differences by gender, age group and Index of Multiple Deprivation quintile. Likelihood of having at least one GP/practice nurse consultation was broadly similar (83.2% vs 80.3% in the COVID-19 cohort). The proportion of patients referred to mental health services in the COVID-19 cohort (4.2%) was around two-thirds of that in the prepandemic cohort (6.1%). Similar proportions were prescribed psychotropic medication within 3 months in the prepandemic (54.0%) and COVID-19 first-wave (54.9%) cohorts. Despite the challenges experienced by primary healthcare teams during the initial COVID-19 wave, prescribing and consultation patterns following self-harm were broadly similar to prepandemic levels. We found no evidence of widening of digital exclusion in terms of access to remote consultations. However, the reduced likelihood of referral to mental health services warrants attention. Accessible outpatient and community services for people who have self-harmed are required as the COVID-19 crisis recedes and the population faces new challenges to mental health.

Identifiants

pubmed: 35165109
pii: bmjopen-2021-052613
doi: 10.1136/bmjopen-2021-052613
pmc: PMC8844953
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e052613

Subventions

Organisme : Medical Research Council
ID : MR/V02843X/1
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: NK reports grants and personal fees from the UK Department of Health and Social Care, the National Institute of Health Research (NIHR), the National Institute for Health and Care Excellence (NICE) and the Healthcare Quality and Improvement Partnership, outside the submitted work; works with NHS England on national quality improvement initiatives for suicide and self-harm; is a member of the advisory group for the National Suicide Prevention Strategy of the Department of Health and Social Care; has chaired NICE guideline committees for Self-harm and Depression; and is currently the Topic Advisor for the new NICE Guidelines for self-harm. All other authors declare no competing interests.

Références

JMIR Med Inform. 2019 Dec 3;7(4):e13042
pubmed: 31793888
Lancet Public Health. 2021 Feb;6(2):e124-e135
pubmed: 33444560
J Affect Disord. 2016 Jun;197:182-8
pubmed: 26994436
JAMA Psychiatry. 2021 Apr 1;78(4):372-379
pubmed: 33533876
Eur J Epidemiol. 2019 Jan;34(1):91-99
pubmed: 30219957
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Br J Psychiatry. 2020 Dec;217(6):717-724
pubmed: 32744207
Br J Gen Pract. 2020 Apr 30;70(694):e364-e373
pubmed: 32041771
Br J Gen Pract. 2020 Dec 28;71(702):e1-e9
pubmed: 33318086
Lancet Digit Health. 2020 Aug;2(8):e395-e396
pubmed: 32835198
Br J Psychiatry. 2021 Jun;218(6):326-333
pubmed: 33081860
F1000Res. 2020 Sep 4;9:1097
pubmed: 33604025
Lancet Psychiatry. 2021 Feb;8(2):e3
pubmed: 33485423
Int J Epidemiol. 2019 Dec 1;48(6):1740-1740g
pubmed: 30859197
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037
Lancet Public Health. 2020 Oct;5(10):e543-e550
pubmed: 32979305
Br J Psychiatry. 2013 May;202(5):326-8
pubmed: 23637107

Auteurs

Sarah Steeg (S)

Centre for Mental Health and Safety, University of Manchester, Manchester, UK sarah.steeg@manchester.ac.uk.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
National Institute for Health Research School for Primary Care Research, University of Manchester, Manchester, UK.

Matthew Carr (M)

Centre for Mental Health and Safety, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Centre for Pharmacoepidemiology and Drug Safety, University of Manchester, Manchester, UK.
National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.

Laszlo Trefan (L)

Centre for Mental Health and Safety, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Darren Ashcroft (D)

Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
National Institute for Health Research School for Primary Care Research, University of Manchester, Manchester, UK.
Centre for Pharmacoepidemiology and Drug Safety, University of Manchester, Manchester, UK.
National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.

Navneet Kapur (N)

Centre for Mental Health and Safety, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.
Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.

Emma Nielsen (E)

Self-harm Research Group, School of Psychology, University of Nottingham, Nottingham, UK.

Brian McMillan (B)

Centre for Primary Care and Health Services Research, University of Manchester, Manchester, UK.

Roger Webb (R)

Centre for Mental Health and Safety, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH